GlassScriptPhysician profile
Carl R Hannah
NPI 1700848363
$14,546.97
in general payments reported to CMS, 2019-2025
53 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,978 · 2020: $1,945 · 2021: $2,902 · 2022: $2,657 · 2023: $2,092 · 2024: $1,771 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,005 · Education: $60.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,005.21 |
| Education | $60.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,603.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,590.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,198.59 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,134.17 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $925.69 | 2019-2025 | Shingrix, Nucala, Arexvy |
| Pfizer INC. | $883.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.89 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $600.18 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $510.34 | 2019-2025 | Rexulti |
| Astellas Pharma US INC | $506.68 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $378.12 | 2021-2025 | |
| Amgen INC. | $367.85 | 2019-2025 | Evenity, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $361.79 | 2019-2024 | Spravato |
| Allergan, INC. | $345.28 | 2019-2020 | |
| Abbott Laboratories | $326.07 | 2021-2024 | Freestyle Libre 3 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Hannah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.